Triptolide suppresses IL-1β-induced expression of interleukin-8 by inhibiting ROS-Mediated ERK, AP-1, and NF-κB...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Triptolide, a compound from Tripterygium wilfordii Hook F, exhibits anticancer and anti-inflammatory properties.
• Interleukin-8 (IL-8) is a pro-inflammatory cytokine linked to cancer progression, including cell proliferation and angiogenesis.
• Gastric cancer involves complex interactions within the tumor microenvironment, influenced by cytokines like IL-8.

Purpose of the Study:

• To investigate the inhibitory effect of Triptolide on IL-1β-induced IL-8 expression in human gastric cancer cells.
• To elucidate the molecular mechanisms underlying Triptolide's action, focusing on reactive oxygen species (ROS), AP-1, and NF-κB signaling pathways.
• To assess the impact of Triptolide on endothelial cell angiogenesis in the tumor microenvironment.

Main Methods:

• Human gastric adenocarcinoma cells (AGS) were treated with IL-1β and varying concentrations of Triptolide.
• Reactive oxygen species (ROS) generation was measured.
• Activation of signaling pathways including ERK, AP-1, and NF-κB was analyzed.

Main Results:

• Triptolide significantly inhibited IL-1β-induced IL-8 expression in gastric cancer cells.
• Triptolide suppressed ROS production, AP-1 activation, and NF-κB activation in a dose-dependent manner.
• The observed inhibition of IL-8 expression and signaling pathways correlated with reduced endothelial cell angiogenetic activity.

Conclusions:

• Triptolide effectively inhibits IL-8 expression in gastric cancer cells by targeting ROS production and downstream signaling pathways (AP-1, NF-κB).
• Triptolide's ability to suppress angiogenesis suggests a role in modulating the tumor microenvironment.
• These findings highlight Triptolide as a potential therapeutic agent for gastric cancer, impacting both cancer cells and their associated microenvironment.